Targeted killing of TNFR2-expressing tumor cells and T
Antibodies, Monoclonal
/ pharmacology
Biomarkers
Cell Line, Tumor
Cell Proliferation
Dipeptidyl Peptidase 4
/ metabolism
Gene Expression
Humans
Immunophenotyping
Lymphocyte Activation
/ drug effects
Neoplasm Staging
Receptors, Tumor Necrosis Factor, Type II
/ antagonists & inhibitors
Sezary Syndrome
/ drug therapy
T-Lymphocytes, Regulatory
/ drug effects
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
25
04
2018
accepted:
17
09
2018
revised:
10
09
2018
pubmed:
26
10
2018
medline:
14
8
2019
entrez:
26
10
2018
Statut:
ppublish
Résumé
Sézary syndrome (SS) is a rare form of cutaneous T-cell lymphoma often refractory to treatment. SS is defined as adenopathy, erythroderma with high numbers of atypical T cells. This offers an opportunity for new interventions and perhaps antibody-based therapeutic by virtue of its high expression of the TNFR2 oncogene on the tumor cells and on T-regulatory cells (T
Identifiants
pubmed: 30356161
doi: 10.1038/s41375-018-0292-9
pii: 10.1038/s41375-018-0292-9
pmc: PMC6756055
doi:
Substances chimiques
Antibodies, Monoclonal
0
Biomarkers
0
Receptors, Tumor Necrosis Factor, Type II
0
Dipeptidyl Peptidase 4
EC 3.4.14.5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1206-1218Références
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.
doi: 10.1182/blood-2016-01-643569
Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115:798–812.
doi: 10.1172/JCI24826
Ungewickell A, Bhaduri A, Rios E, Reuter J, Lee CS, Mah A, et al. Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015;47:1056–60.
doi: 10.1038/ng.3370
Byrne WL, Mills KH, Lederer JA, O’Sullivan GC. Targeting regulatory T cells in cancer. Cancer Res. 2011;71:6915–20.
doi: 10.1158/0008-5472.CAN-11-1156
Teng MW, Ritchie DS, Neeson P, Smyth MJ. Biology and clinical observations of regulatory T cells in cancer immunology. Curr Top Microbiol Immunol. 2011;344:61–95.
pubmed: 20512555
Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012;72:2162–71.
doi: 10.1158/0008-5472.CAN-11-3687
Chen X, Subleski JJ, Kopf H, Howard OM, Mannel DN, Oppenheim JJ. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4 + CD25 + FoxP3 + T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol. 2008;180:6467–71.
doi: 10.4049/jimmunol.180.10.6467
Chen X, Subleski JJ, Hamano R, Howard OMZ, Wiltrout RH, Oppenheim JJ. Co-expression of TNFR2 and CD25 identifies more of the functional CD4( + )FOXP3( + ) regulatory T cells in human peripheral blood. Eur J Immunol. 2010;40:1099–106.
doi: 10.1002/eji.200940022
Govindaraj C, Scalzo-Inguanti K, Madondo M, Hallo J, Flanagan K, Quinn M, et al. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2 + Tregs within the tumor microenvironment. Clin Immunol. 2013;149:97–110.
doi: 10.1016/j.clim.2013.07.003
Vanamee ES, Faustman DL. TNFR2: a novel target for cancer immunotherapy. Trends Mol Med. 2017;23:1037–46.
doi: 10.1016/j.molmed.2017.09.007
Okubo Y, Mera T, Wang L, Faustman DL. Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci Rep. 2013;3:3153.
doi: 10.1038/srep03153
Vanamee ES, Faustman DL. Structural principles of tumor necrosis factor superfamily signaling. Sci Signal. 2018; 11:eaao4910.
doi: 10.1126/scisignal.aao4910
Torrey H, Butterworth J, Mera T, Okubo Y, Wang L, Baum D, et al. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci Signal. 2017;10:eaaf8608.
doi: 10.1126/scisignal.aaf8608
Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteom. 2005;4:1920–32.
doi: 10.1074/mcp.M500279-MCP200
Drake CG, Lipson EJ, Brahmer JR. Reply: Regulatory T cells-an important target for cancer immunotherapy. Nat Rev Clin Oncol. 2014;11:307.
doi: 10.1038/nrclinonc.2013.208-c2
Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278–87.
doi: 10.1038/nrc3236
Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9:606–12.
pubmed: 12576425
Zhang W, Sharma R, Ju ST, He XS, Tao Y, Tsuneyama K, et al. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatology. 2009;49:545–52.
doi: 10.1002/hep.22651
Li Q, Zhai Z, Xu X, Shen Y, Zhang A, Sun Z, et al. Decrease of CD4( + )CD25( + ) regulatory T cells and TGF-beta at early immune reconstitution is associated to the onset and severity of graft-versus-host disease following allogeneic haematogenesis stem cell transplantation. Leuk Res. 2010;34:1158–68.
doi: 10.1016/j.leukres.2010.03.017
Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, et al. Selective depletion of Foxp3 + regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010;70:7788–99.
doi: 10.1158/0008-5472.CAN-10-1736
Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25 + CD4 + T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211–8.
pubmed: 10553041
Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25( + ) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001;194:823–32.
doi: 10.1084/jem.194.6.823
Smyth MJ, Ngiow SF, Teng MW. Targeting regulatory T cells in tumor immunotherapy. Immunol Cell Biol. 2014;92:473–4.
doi: 10.1038/icb.2014.33
Heinrich M, Burger D, Wang L, Tahhan G, Reinhold P, Zhao M, et al. TNFR1 and TNFR2 expression and induction on human Treg cells from type 1 diabetic subjects. Antibodies. 2015;4:34–47.
doi: 10.3390/antib4010034
Polz J, Remke A, Weber S, Schmidt D, Weber-Steffens D, Pietryga-Krieger A, et al. Myeloid suppressor cells require membrane TNFR2 expression for suppressive activity. Immun Inflamm Dis. 2014;2:121–30.
doi: 10.1002/iid3.19
Welborn MB III, Van Zee K, Edwards PD, Pruitt JH, Kaibara A, Vauthey JN, et al. A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. J Exp Med. 1996;184:165–71.
doi: 10.1084/jem.184.1.165
Chen X, Wu X, Zhou Q, Howard OM, Netea MG, Oppenheim JJ. TNFR2 is critical for the stabilization of the CD4 + Foxp3 + regulatory T. cell phenotype in the inflammatory environment. J Immunol. 2013;190:1076–84.
doi: 10.4049/jimmunol.1202659
Govindaraj C, Tan P, Walker P, Wei A, Spencer A, Plebanski M. Reducing TNF receptor 2 + regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients. Clin Cancer Res. 2014;20:724–35.
doi: 10.1158/1078-0432.CCR-13-1576
Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, et al. A four-marker signature of TNF-RII, TGF-alpha, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med. 2014;12:19.
doi: 10.1186/1479-5876-12-19
Heemann C, Kreuz M, Stoller I, Schoof N, von Bonin F, Ziepert M, et al. Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma. Clin Cancer Res. 2012;18:3637–47.
doi: 10.1158/1078-0432.CCR-11-3299
Babic A, Shah SM, Song M, Wu K, Meyerhardt JA, Ogino S, et al. Soluble tumour necrosis factor receptor type II and survival in colorectal cancer. Br J Cancer. 2016;114:995–1002.
doi: 10.1038/bjc.2016.85
Warzocha K, Bienvenu J, Ribeiro P, Moullet I, Dumontet C, Neidhardt-Berard EM, et al. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin’s disease patients. Br J Cancer. 1998;77:2357–62.
doi: 10.1038/bjc.1998.391
Dobrzycka B, Terlikowski SJ, Kowalczuk O, Kinalski M. Circulating levels of TNF-alpha and its soluble receptors in the plasma of patients with epithelial ovarian cancer. Eur Cytokine Netw. 2009;20:131–4.
pubmed: 19825522
Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001;115:885–92.
doi: 10.1309/U1Y6-J4AG-5M4M-7AYV
Rappl G, Abken H, Muche JM, Sterry W, Tilgen W, Andre S, et al. CD4 + CD7- leukemic T cells from patients with Sezary syndrome are protected from galectin-1-triggered T cell death. Leukemia. 2002;16:840–5.
doi: 10.1038/sj.leu.2402438
Lee CS, Ungewickell A, Bhaduri A, Qu K, Webster DE, Armstrong R, et al. Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. Blood. 2012;120:3288–97.
doi: 10.1182/blood-2012-04-423061
Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352:189–96.
doi: 10.1126/science.aad0501
Torrey H, Defusco A, Baum D, Rhabar Z, Khodadoust M, Kim YH et al. Novel treatment of cutaneous T cell lymphoma: targetting TNFR2 an oncogene and marker of potent Treg. Cancer Research 78 (13 Suppl):1790–1790.
Wang L, Xiao N, et al. Genomic profiling of Sezary Syndrome identifeis alternations of key T-cell singaling and differentiation genes. Nat Genet. 2015;47:1426–34.
doi: 10.1038/ng.3444
da Silva Almeida A, Abate F, Khiabanian H, et al. The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome. Nat Genet. 2015;47:1465–70.
doi: 10.1038/ng.3442
Choi J, Goh G, Walradt T. et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47:1011–9.
doi: 10.1038/ng.3356
Ni X, Jorgensen JL, Goswami M, Challagundla P, Decker WK, Kim YH, et al. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sezary syndrome. Clin Cancer Res. 2015;21:274–85.
doi: 10.1158/1078-0432.CCR-14-0830
Nie Y, He J, Shirota H, Trivett AL, Yang, Klinman DM, et al. Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer. Sci Signal. 2018;11:eaan0790.
doi: 10.1126/scisignal.aan0790